Alex Carchidi
Alex Carchidi is a contributing Healthcare and Cryptocurrency Analyst at The Motley Fool, covering publicly traded companies and investments in the biotech, pharma, cannabis, and digital asset industries. Prior to The Motley Fool, Alex was a bench scientist and later a science writer at several biopharma companies, and started his career as a researcher at the Ragon Institute of MGH, MIT, and Harvard. He holds a B.A. in Biology and a B.A. in Philosophy from Boston University, and an MBA with a concentration in Finance from the Isenberg School of Business at the University of Massachusetts, Amherst. In his spare time, Alex enjoys traveling in Latin America and exploring the food scene of Greater Boston.
Recent Articles by Alex Carchidi

Got $3,000? Buy These 2 Cryptocurrencies Right Now.

Is Melania Trump's Meme Coin a Buy?

1 Huge New Reason Meme Coins Will Go Higher in 2025

3 Things You Need to Know if You Buy Moderna Today

3 Mistakes to Avoid With Solana in 2025

3 Reasons Solana Could Go to $500 or Higher in 2025

Where Will Moderna Be in 3 Years?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.